Drug Trial Radar · NCT04559204
Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4
Last checked: Nov 19, 2026Latest source record: Aug 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,224
Actual
Start
Sep 11, 2020
Primary completion
Nov 26, 2020
Study completion Oct 9, 2021
Sponsor
- Lead sponsor
- China National Biotec Group Company LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Center for Disease Control and Prevention, Fujian; Chengdu Institute of Biological Products Co.,Ltd.; Changchun Institute of Biological Products Co., Ltd.; National Institutes for Food and Drug Control, China; Guizhou Center for Disease Control and Prevention; Hunan Provincial Center for Disease Control and Prevention; Peking University
- First posted
- Sep 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Subjects will be recruited and divided into 3 groups: 1. Experimental Group (408 subjects): combined immunization of PPV23 and IIV4; 2. Control Group A (408 subjects): IIV4 only; 3. Control Group B (408 subjects): PPV23 only; All blood samples will be collected before and one month after vaccinatioin. The immunogenicity and safety of both experimental and control groups will be compared and the data be analyzed.
Conditions
- Influenza, Human
- Pneumonia, Pneumococcal
Interventions
IIV4 and PPV23Biological
imultaneously immunization of 23-valent pneumococcal polysaccharide vaccine (PPV23) and quadrivalent inactivated influenza vaccine (IIV4)
IIV4Biological
administrated with IIV4 only
PPV23Biological
administrated with PPV23 only
Primary outcomes
What the sponsor says the trial is designed to measure.
- Seroconversion rate (IIV4)Time frame: Baseline (before vaccination) results
- Seroconversion rate (IIV4)Time frame: Results obtained 1 month after vaccination
- Seroconversion rate (PPV23)Time frame: Baseline (before vaccination) results
- Seroconversion rate (PPV23)Time frame: Results obtained 1 month after vaccination
- Geometric Mean Concentration (GMC) (IIV4)Time frame: Baseline (before vaccination) results
- Geometric Mean Concentration (GMC) (IIV4)Time frame: Results obtained 1 month after vaccination
- Geometric Mean Concentration (GMC) (PPV23)Time frame: Baseline (before vaccination) results
- Geometric Mean Concentration (GMC) (PPV23)Time frame: Results obtained 1 month after vaccination
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Liucheng Community Health Services Center
Quanzhou, Fujian, China
Luodong County Health Center
Quanzhou, Fujian, China
Qingzhen Center for Disease Control and Prevention
Qingzhen, Guizhou, China
Qidong County Center for Disease Control and Prevention
Hongqiao, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.